RU2691123C1 - Способ получения материала с высоким титром вируса гепатита Е и анализ титрования вируса гепатита Е - Google Patents

Способ получения материала с высоким титром вируса гепатита Е и анализ титрования вируса гепатита Е Download PDF

Info

Publication number
RU2691123C1
RU2691123C1 RU2016127546A RU2016127546A RU2691123C1 RU 2691123 C1 RU2691123 C1 RU 2691123C1 RU 2016127546 A RU2016127546 A RU 2016127546A RU 2016127546 A RU2016127546 A RU 2016127546A RU 2691123 C1 RU2691123 C1 RU 2691123C1
Authority
RU
Russia
Prior art keywords
hev
copies
hepg2
reaction mixture
virus
Prior art date
Application number
RU2016127546A
Other languages
English (en)
Russian (ru)
Inventor
Бретт БУНО
Терри ДЖОРНИГАН
Джоанн ХОТТА
Майкл БЕРДИК
Original Assignee
Грифольс, С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Грифольс, С.А. filed Critical Грифольс, С.А.
Application granted granted Critical
Publication of RU2691123C1 publication Critical patent/RU2691123C1/ru

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/02—Recovery or purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C12Q1/707—Specific hybridization probes for hepatitis non-A, non-B Hepatitis, excluding hepatitis D
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/30—Organic components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/28011—Hepeviridae
    • C12N2770/28111—Hepevirus, e.g. hepatitis E virus
    • C12N2770/28151—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
RU2016127546A 2015-07-23 2016-07-08 Способ получения материала с высоким титром вируса гепатита Е и анализ титрования вируса гепатита Е RU2691123C1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562195936P 2015-07-23 2015-07-23
US62/195,936 2015-07-23

Publications (1)

Publication Number Publication Date
RU2691123C1 true RU2691123C1 (ru) 2019-06-11

Family

ID=56409494

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2016127546A RU2691123C1 (ru) 2015-07-23 2016-07-08 Способ получения материала с высоким титром вируса гепатита Е и анализ титрования вируса гепатита Е

Country Status (22)

Country Link
US (1) US10208291B2 (cg-RX-API-DMAC7.html)
EP (1) EP3121267B1 (cg-RX-API-DMAC7.html)
JP (1) JP6588397B2 (cg-RX-API-DMAC7.html)
KR (1) KR102154380B1 (cg-RX-API-DMAC7.html)
CN (1) CN106367397B (cg-RX-API-DMAC7.html)
AR (1) AR106015A1 (cg-RX-API-DMAC7.html)
AU (1) AU2016204734B2 (cg-RX-API-DMAC7.html)
BR (1) BR102016016677A2 (cg-RX-API-DMAC7.html)
CA (1) CA2937088C (cg-RX-API-DMAC7.html)
CL (1) CL2016001768A1 (cg-RX-API-DMAC7.html)
ES (1) ES2669021T3 (cg-RX-API-DMAC7.html)
HU (1) HUE036699T2 (cg-RX-API-DMAC7.html)
IL (1) IL246634B (cg-RX-API-DMAC7.html)
MX (1) MX375106B (cg-RX-API-DMAC7.html)
MY (1) MY176204A (cg-RX-API-DMAC7.html)
NZ (1) NZ722213A (cg-RX-API-DMAC7.html)
PL (1) PL3121267T3 (cg-RX-API-DMAC7.html)
PT (1) PT3121267T (cg-RX-API-DMAC7.html)
RU (1) RU2691123C1 (cg-RX-API-DMAC7.html)
SG (1) SG10201605867UA (cg-RX-API-DMAC7.html)
TW (1) TWI666322B (cg-RX-API-DMAC7.html)
UY (1) UY36778A (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102158641B1 (ko) * 2019-03-06 2020-09-22 대한민국 야누스 인산화효소 저해제 및 헥사디메트린 브로마이드를 포함하는 바이러스 배양용 조성물 및 이를 이용한 바이러스 배양 방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003001198A1 (en) * 2001-06-21 2003-01-03 Regents Of The University Of California Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase
US7252991B2 (en) * 1993-06-11 2007-08-07 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
US20130004471A1 (en) * 2011-06-10 2013-01-03 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6217858B1 (en) * 1997-02-11 2001-04-17 Hadasit & Medical Research Services & Development Company, Ltd. Pharmaceutical composition for treating hepatitis B virus (HBV) infection
WO2007046962A2 (en) * 2005-09-02 2007-04-26 The University Of Maryland, Baltimore Cell lines harboring hepatitis virus and methods for using thereof
WO2010040001A1 (en) * 2008-10-03 2010-04-08 The Rockefeller University New hcv entry factor, occludin
EP2663328B1 (en) 2011-01-10 2018-09-19 The Government of The United States of America, as represented by The Secretary, Department of Health and Human Services Infectious hepatitis e virus genotype 3 or 1 recombinants

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7252991B2 (en) * 1993-06-11 2007-08-07 Cell Genesys, Inc. Method for production of high titer virus and high efficiency retroviral mediated transduction of mammalian cells
WO2003001198A1 (en) * 2001-06-21 2003-01-03 Regents Of The University Of California Immortalization of human cells by the ectopic expression of human telomerase reverse transcriptase
US20130004471A1 (en) * 2011-06-10 2013-01-03 Bluebird Bio, Inc. Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DEL VECCHIO MA., et al., Approaches to enhancing the retroviral transduction of human synoviocytes.Arthritis Res. 2001;3(4):259-63. Epub 2001 May 18. *
YANG F., et al., [The establishment of high-throughput neutralization titer evaluation model for hepatitis E virus (HEV)].[Article in Chinese], Bing Du Xue Bao. 2015 Jan;31(1):1-6. *

Also Published As

Publication number Publication date
TW201704468A (zh) 2017-02-01
IL246634A0 (en) 2016-12-29
AU2016204734A1 (en) 2017-02-09
CA2937088C (en) 2022-06-21
CN106367397B (zh) 2021-07-20
JP2017023143A (ja) 2017-02-02
AR106015A1 (es) 2017-12-06
CL2016001768A1 (es) 2017-05-12
NZ722213A (en) 2019-04-26
ES2669021T3 (es) 2018-05-23
HUE036699T2 (hu) 2018-07-30
BR102016016677A2 (pt) 2019-02-12
IL246634B (en) 2020-08-31
KR20170012140A (ko) 2017-02-02
PT3121267T (pt) 2018-04-26
MX375106B (es) 2025-03-06
UY36778A (es) 2016-09-30
MY176204A (en) 2020-07-24
SG10201605867UA (en) 2017-02-27
MX2016009048A (es) 2017-01-23
JP6588397B2 (ja) 2019-10-09
EP3121267A1 (en) 2017-01-25
US10208291B2 (en) 2019-02-19
KR102154380B1 (ko) 2020-09-10
AU2016204734B2 (en) 2019-11-21
EP3121267B1 (en) 2018-03-28
TWI666322B (zh) 2019-07-21
PL3121267T3 (pl) 2018-07-31
CN106367397A (zh) 2017-02-01
US20170022481A1 (en) 2017-01-26
CA2937088A1 (en) 2017-01-23

Similar Documents

Publication Publication Date Title
Pfaender et al. Clinical course of infection and viral tissue tropism of hepatitis C virus–like nonprimate hepaciviruses in horses
de Deus et al. Detection of hepatitis E virus in liver, mesenteric lymph node, serum, bile and faeces of naturally infected pigs affected by different pathological conditions
Chan et al. Persistent infection of SARS coronavirus in colonic cells in vitro
Guillaume et al. Specific detection of Nipah virus using real-time RT-PCR (TaqMan)
EP2954055B1 (en) Cell lines for virus production and methods of use
Gillim-Ross et al. Discovery of novel human and animal cells infected by the severe acute respiratory syndrome coronavirus by replication-specific multiplex reverse transcription-PCR
Sridhar et al. A systematic approach to novel virus discovery in emerging infectious disease outbreaks
Banach et al. Human airway epithelial cell culture to identify new respiratory viruses: coronavirus NL63 as a model
Xia et al. Isolation and characterization of a pangolin-borne HKU4-related coronavirus that potentially infects human-DPP4-transgenic mice
Nagashima et al. Characteristics of SARS-CoV-2 isolated from asymptomatic carriers in Tokyo
Roth et al. Isolation of influenza viruses in MDCK 33016PF cells and clearance of contaminating respiratory viruses
RU2691026C1 (ru) Способы очистки вируса, продуцированного in vitro, и анализ элиминации вируса
Gong et al. Genetic characterization of hepatitis E virus from wild boar in China
JP6588397B2 (ja) 高力価のｅ型肝炎ウイルスストックを生成する方法及びｅ型肝炎ウイルスの力価測定アッセイ
Kumar et al. Lumpy skin disease virus suppresses the antiviral response of bovine peripheral blood mononuclear cells that support viral dissemination
HK1230654B (en) Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus
HK1230654A1 (en) Method for generating high-titer hepatitis e virus stocks and titration assay for hepatitis e virus
CN117925540B (zh) 一种cv2117-hav-htlv-2多基因假病毒及其制备方法和应用
Widera et al. Generation of a Sleeping Beauty transposon-based cellular system for rapid and sensitive identification of SARS-CoV-2 host dependency and restriction factors
Valade et al. Development of cell combos micromethod to isolate respiratory viruses not detected by molecular techniques
Viedma Methodological Biases in Virology: A Scientific Criteria-Based Review of Purification, Sequencing and Infectivity Studies
Rajalakshmy et al. Serum‐derived hepatitis C virus 1a infection of human astrocyte cell line SVG
Laksono et al. The potential role of human immune cells in the systemic dissemination of enterovirus-D68
US20100215696A1 (en) Efficiently replicable heptitis c virus mutant, a heptitis c virus mutant comprising reporter gene, a method of preparing of hcv vaccine using the same and a method of screening anti hcv composition using the same
Harms The role of host cellular and viral evolutionary factors influencing the replication mechanisms of chronic hepatitis E virus infection in vivo and in vitro